Moderna in Discussions to Supply Japan with Doses of its COVID-19 Vaccine Candidate
The vaccine will be supplied by Moderna and distributed in Japan by Takeda Pharmaceutical starting in the first half of 2021 if the vaccine candidate receives regulatory approval.
Moderna announced on Aug. 28, 2020 that it is in discussions with the Ministry of Health, Labour and Welfare of Japan (MHLW) to purchase 40 million or more doses of mRNA-1273, Moderna’s COVID-19 vaccine candidate.
Through the agreement, the vaccine will be supplied by Moderna and distributed in Japan by Takeda Pharmaceutical starting in the first half of 2021 if the vaccine candidate receives regulatory approval, a Moderna press release said.
Source: Moderna
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 5th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
